Expanding the Reach of Monoclonal Antibodies through Synthetic Nucleic Acid Delivery in Immunotherapy

Immunotherapy has revolutionized the treatment of various diseases by harnessing the immune system to combat disease. A new method of delivering monoclonal antibodies, crucial for immunotherapy, is being explored to increase their accessibility and utility. Researchers from GeneOne Life Science Inc. have developed a review highlighting the potential of synthetic nucleic acid delivery in overcoming the limitations of monoclonal antibody production and administration.

Key Takeaways:

• The production and administration of monoclonal antibodies are laborious, costly, and time-consuming, limiting their use in underserved populations and developing countries.
• Researchers are developing alternate methods to deliver monoclonal antibodies, including synthetic nucleic acid-based delivery.
• Synthetic nucleic acid delivery allows for in vivo production of monoclonal antibodies, reducing costs and simplifying administration logistics.
• This method could significantly increase the accessibility and utility of life-saving treatments for several diseases.
• Monoclonal antibodies target specific epitopes of single molecules, minimizing off-target effects and activating or suppressing certain pathways.
• GeneOne Life Science Inc. is at the forefront of this research, led by experts such as Christopher Chung, Sagar B. Kudchodkar, and Norbert Pardi.

Statistics:

• The majority of monoclonal antibodies are developed from naturally occurring antibodies.
• These antibodies are often administered inpatient, requiring repeated dosing to maintain therapeutic levels.
• Synthetic nucleic acid delivery aims to reduce the production and administration costs of monoclonal antibodies.
• This method could benefit millions of patients worldwide, particularly in underserved populations and developing countries.
• According to the review, synthetic nucleic acid delivery is a promising area of research for increasing the accessibility and utility of monoclonal antibodies.

Sources:

• Antibodies, 2023, 12(3)
• Gomez, J. A. et al. (2018). A secretable and functional single-chain antibody. Nature Communications, 9(1), 1-12.
• Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy. Antibodies. 2023, 12(3).